vs
Apellis Pharmaceuticals, Inc.（APLS）与Federal Realty Investment Trust（FRT）财务数据对比。点击上方公司名可切换其他公司
Federal Realty Investment Trust的季度营收约是Apellis Pharmaceuticals, Inc.的1.7倍（$336.0M vs $199.9M），Federal Realty Investment Trust净利率更高（38.6% vs -29.5%，领先68.1%），Federal Realty Investment Trust同比增速更快（8.7% vs -5.9%），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs 6.5%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
Federal Realty Investment Trust是一家专业房地产投资信托基金，核心投资标的为购物中心类商业物业，资产布局覆盖美国东北部、大西洋中部地区、加利福尼亚州及南佛罗里达区域，在当地商业不动产投资领域拥有丰富的运营经验。
APLS vs FRT — 直观对比
营收规模更大
FRT
是对方的1.7倍
$199.9M
营收增速更快
FRT
高出14.6%
-5.9%
净利率更高
FRT
高出68.1%
-29.5%
两年增速更快
APLS
近两年复合增速
6.5%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $336.0M |
| 净利润 | $-59.0M | $129.7M |
| 毛利率 | — | — |
| 营业利润率 | -25.6% | 53.8% |
| 净利率 | -29.5% | 38.6% |
| 营收同比 | -5.9% | 8.7% |
| 净利润同比 | -62.2% | 103.5% |
| 每股收益（稀释后） | $-0.40 | $1.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSFRT
| Q1 26 | — | $336.0M | ||
| Q4 25 | $199.9M | $336.0M | ||
| Q3 25 | $458.6M | $322.3M | ||
| Q2 25 | $178.5M | $311.5M | ||
| Q1 25 | $166.8M | $309.2M | ||
| Q4 24 | $212.5M | $311.4M | ||
| Q3 24 | $196.8M | $303.6M | ||
| Q2 24 | $199.7M | $296.1M |
净利润APLSFRT
| Q1 26 | — | $129.7M | ||
| Q4 25 | $-59.0M | $129.7M | ||
| Q3 25 | $215.7M | $61.6M | ||
| Q2 25 | $-42.2M | $155.9M | ||
| Q1 25 | $-92.2M | $63.8M | ||
| Q4 24 | $-36.4M | $65.5M | ||
| Q3 24 | $-57.4M | $61.0M | ||
| Q2 24 | $-37.7M | $112.0M |
营业利润率APLSFRT
| Q1 26 | — | 53.8% | ||
| Q4 25 | -25.6% | 53.8% | ||
| Q3 25 | 48.7% | 34.3% | ||
| Q2 25 | -18.6% | 65.1% | ||
| Q1 25 | -50.0% | 35.0% | ||
| Q4 24 | -12.3% | 35.1% | ||
| Q3 24 | -24.0% | 34.9% | ||
| Q2 24 | -14.7% | 53.0% |
净利率APLSFRT
| Q1 26 | — | 38.6% | ||
| Q4 25 | -29.5% | 38.6% | ||
| Q3 25 | 47.0% | 19.1% | ||
| Q2 25 | -23.6% | 50.0% | ||
| Q1 25 | -55.3% | 20.6% | ||
| Q4 24 | -17.1% | 21.0% | ||
| Q3 24 | -29.2% | 20.1% | ||
| Q2 24 | -18.9% | 37.8% |
每股收益（稀释后）APLSFRT
| Q1 26 | — | $1.49 | ||
| Q4 25 | $-0.40 | $1.49 | ||
| Q3 25 | $1.67 | $0.69 | ||
| Q2 25 | $-0.33 | $1.78 | ||
| Q1 25 | $-0.74 | $0.72 | ||
| Q4 24 | $-0.30 | $0.74 | ||
| Q3 24 | $-0.46 | $0.70 | ||
| Q2 24 | $-0.30 | $1.32 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $107.4M |
| 总债务越低越好 | — | $5.0B |
| 股东权益账面价值 | $370.1M | $3.2B |
| 总资产 | $1.1B | $9.1B |
| 负债/权益比越低杠杆越低 | — | 1.53× |
8季度趋势，按日历期对齐
现金及短期投资APLSFRT
| Q1 26 | — | $107.4M | ||
| Q4 25 | $466.2M | $107.4M | ||
| Q3 25 | $479.2M | $111.3M | ||
| Q2 25 | $370.0M | $177.0M | ||
| Q1 25 | $358.4M | $109.2M | ||
| Q4 24 | $411.3M | $123.4M | ||
| Q3 24 | $396.9M | $97.0M | ||
| Q2 24 | $360.1M | $103.2M |
总债务APLSFRT
| Q1 26 | — | $5.0B | ||
| Q4 25 | — | $5.0B | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $4.5B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益APLSFRT
| Q1 26 | — | $3.2B | ||
| Q4 25 | $370.1M | $3.2B | ||
| Q3 25 | $401.2M | $3.2B | ||
| Q2 25 | $156.3M | $3.2B | ||
| Q1 25 | $164.2M | $3.2B | ||
| Q4 24 | $228.5M | $3.2B | ||
| Q3 24 | $237.1M | $3.1B | ||
| Q2 24 | $264.3M | $3.0B |
总资产APLSFRT
| Q1 26 | — | $9.1B | ||
| Q4 25 | $1.1B | $9.1B | ||
| Q3 25 | $1.1B | $8.9B | ||
| Q2 25 | $821.4M | $8.6B | ||
| Q1 25 | $807.3M | $8.6B | ||
| Q4 24 | $885.1M | $8.5B | ||
| Q3 24 | $901.9M | $8.5B | ||
| Q2 24 | $904.5M | $8.4B |
负债/权益比APLSFRT
| Q1 26 | — | 1.53× | ||
| Q4 25 | — | 1.53× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 1.42× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | — |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | — |
| 自由现金流率自由现金流/营收 | -7.1% | — |
| 资本支出强度资本支出/营收 | 0.1% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | — |
8季度趋势，按日历期对齐
经营现金流APLSFRT
| Q1 26 | — | — | ||
| Q4 25 | $-14.2M | $622.4M | ||
| Q3 25 | $108.5M | $147.8M | ||
| Q2 25 | $4.4M | $150.7M | ||
| Q1 25 | $-53.4M | $179.0M | ||
| Q4 24 | $19.4M | $574.6M | ||
| Q3 24 | $34.1M | $144.1M | ||
| Q2 24 | $-8.3M | $169.7M |
自由现金流APLSFRT
| Q1 26 | — | — | ||
| Q4 25 | $-14.3M | — | ||
| Q3 25 | $108.3M | — | ||
| Q2 25 | $4.4M | — | ||
| Q1 25 | $-53.4M | — | ||
| Q4 24 | $19.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-8.4M | — |
自由现金流率APLSFRT
| Q1 26 | — | — | ||
| Q4 25 | -7.1% | — | ||
| Q3 25 | 23.6% | — | ||
| Q2 25 | 2.5% | — | ||
| Q1 25 | -32.0% | — | ||
| Q4 24 | 9.1% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -4.2% | — |
资本支出强度APLSFRT
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.0% | — |
现金转化率APLSFRT
| Q1 26 | — | — | ||
| Q4 25 | — | 4.80× | ||
| Q3 25 | 0.50× | 2.40× | ||
| Q2 25 | — | 0.97× | ||
| Q1 25 | — | 2.81× | ||
| Q4 24 | — | 8.77× | ||
| Q3 24 | — | 2.36× | ||
| Q2 24 | — | 1.52× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
FRT
暂无分部数据
